Abstract
THERE is much evidence to indicate an important role for activated macrophages in resistance to malignant tumours and to infections caused by intracellular pathogens. Different investigators have found that activated macrophages may be distinguished from normal macrophages by either morphological, biochemical, or functional criteria, depending on the experimental design1. Functional criteria frequently cited are killing of intracellular organisms2,3, inhibition and/or killing of tumour cells4–6 and inhibition of proliferating lymphocytes7,8. Previous work in our laboratory has demonstrated that macrophages activated by several methods have always exhibited each of these three functional capacities. For example, macrophages activated by either chronic infection with C56 strain Toxoplasma gondii or by killed Corynebacterium parvum inhibited multiplication of T. gondii9–11, DNA synthesis by tumour target cells12,13, and mitogen- and antigen-specific lymphocyte transformation14. Whether different populations of activated macrophages which have been defined by one functional criterion always possess the other functional capacities of activated macrophages as well, however, has not been established. We report here that activated macrophages characterised by one functional criterion do not necessarily possess other functional characteristics of activated macrophages and that differences in functional capacity depend on the method used to activate the macrophages.
Similar content being viewed by others
References
Allison, A. C. & Davies, P. in Mononuclear Phagocytes in Immunity, Infection and Pathology (ed. van Furth, R.) 487–506 (Blackwell, London, 1975).
Mackaness, G. B. J. exp. Med. 116, 381–406 (1962).
Mackaness, G. B. J. exp. Med. 120, 105–120 (1964).
Evans, R. & Alexander, P. Nature 228, 620–622 (1970).
Alexander, P. & Evans, R. Nature new Biol. 232, 76–78 (1971).
Hibbs, J. B., Jr et al. Science 177, 998–1000 (1972).
Nelson, D. S. Nature 246, 306–307 (1973).
Keller, R. Cell. Immun. 17, 542–551 (1975).
Ruskin, J. et al. J. Immun. 103, 252–259 (1969).
Remington, J. S. et al. Infect. Immun. 6, 829–834 (1972).
Swartzberg, J. E. et al. Infect. Immun. 12, 1037–1043 (1975).
Remington, J. S. et al. in Mononuclear Phagocytes in Immunity, Infection and Pathology (ed. van Furth, R.) 869–894 (Blackwell, London, 1975).
Krahenbuhl, J. L. & Lambert, L. H. J. natn. Cancer Inst. 54, 1433–1437 (1975).
Wing, E. J. & Remington, J. S. Cell. Immun. 30, 108–121 (1977).
Weatherly, N. F. J. Parasitol. 56, 748–752 (1970).
Gardner, I. D. & Remington, J. S. (submitted for publication).
Krahenbuhl, J. L. & Remington, J. S. J. Immun. 113, 507–516 (1974).
Anderson, S. E. & Remington, J. S. J. exp. Med. 139, 1154–1174 (1974).
Walker, W. S. in Immunobiology of the Macrophage (ed. Nelson, D. S.) 91–110 (Academic, New York, 1976).
Walker, W. S. J. reticuloendothel. Soc. 20, 57–65 (1976).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
WING, E., GARDNER, I., RYNING, F. et al. Dissociation of effector functions in populations of activated macrophages. Nature 268, 642–644 (1977). https://doi.org/10.1038/268642a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/268642a0
- Springer Nature Limited
This article is cited by
-
Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection
Journal of Neuroinflammation (2008)
-
The experimental and clinical use of immune-modulating drugs in the prophylaxis and treatment of infections
Infection (1985)
-
The experimental and clinical use of immune-modulating drugs in the prophylaxis and treatment of infections
Infection (1984)